ABCG2 and colorectal carcinoma: Essentially, CRC tumor-spheres treated with MSI-N1014 showed significantly reduced expressions of LGR5, β-catenin, and ABCG2, and reduced resistance against 5-FU, with an increased level of microRNA (miR)-142-3p, which targets both LGR5 and ABCG2.